2023业务调整承压，24Q1现回暖迹象

Investment Rating - The report assigns a "Buy" rating for the company, with a target price of 7.5 RMB per share [1]. Core Insights - The company experienced a revenue decline of 4.5% year-on-year in 2023, with a total revenue of 6.08 billion RMB. However, there are signs of recovery in Q1 2024, with a revenue increase of 4.2% year-on-year [1]. - The medical terminal business showed high growth, while the skincare segment faced challenges due to adjustments, leading to a 42% decline in net profit for 2023 [1]. - The company is expected to achieve net profits of 830 million RMB, 990 million RMB, and 1.08 billion RMB for the years 2024, 2025, and 2026, respectively, indicating a growth trajectory [2]. Summary by Sections Company Overview - The company reported a net profit of 490 million RMB in 2023, down 42% year-on-year, with a revenue of 6.08 billion RMB, a decrease of 4.5% [1]. - In Q1 2024, the company achieved a revenue of 1.36 billion RMB, a year-on-year increase of 4.2%, and a net profit of 240 million RMB, up 21.4% [1]. Financial Performance - The company’s earnings per share (EPS) for 2024 is projected to be 1.72 RMB, with a P/E ratio of 36 [2]. - The company plans to distribute a cash dividend of 3.8 RMB for every 10 shares held [1]. Revenue Breakdown - The medical terminal business generated a revenue of 1.13 billion RMB in 2023, reflecting a growth of 15.2% year-on-year [1]. - The company’s raw material business is expected to maintain steady growth, with a focus on expanding overseas and new business areas [1]. Market Position - The company’s market capitalization is approximately 12.19 billion RMB, with major shareholders including Huaxi Xinyu Investment Co., Ltd [1]. - The company’s stock price has shown a decline of 9% over the past year, with a current price of 61.50 RMB as of April 30, 2024 [1].